<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Poststroke <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> are associated with lower thrombolytic efficacy and an increased risk of postischemic <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to develop a <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent model</z:e> of thrombolysis in diabetic <z:hpo ids='HP_0001297'>stroke</z:hpo> that mimics the clinical situation </plain></SENT>
<SENT sid="2" pm="."><plain>Method- Male 6-week Type I diabetic rats (14 weeks old) were subjected to embolic focal <z:hpo ids='HP_0001297'>stroke</z:hpo> and treated with tissue-type plasminogen activator at 1.5 hours </plain></SENT>
<SENT sid="3" pm="."><plain>Reperfusion and 24-hour neurological outcomes were measured and compared with nondiabetic control rats </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Diabetic rats exhibited resistance to thrombolytic reperfusion, larger infarction volumes, and increased <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: This animal model would be relevant to future studies investigating pathophysiological mechanisms and in developing new therapeutic approaches to enhance the efficacy of tissue-type plasminogen activator thrombolysis in <z:hpo ids='HP_0001297'>stroke</z:hpo> patients with <z:mp ids='MP_0002055'>diabetes</z:mp> or poststroke <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> </plain></SENT>
</text></document>